Literature DB >> 19295367

Repeat selective laser trabeculoplasty.

Bryan Kun Hong1, Jeffrey C Winer, James F Martone, Martin Wand, Bruce Altman, Bruce Shields.   

Abstract

PURPOSE: To evaluate the efficacy of repeat 360-degree selective laser trabeculoplasty (SLT) in glaucoma patients with prior successful 360-degree SLT.
DESIGN: Retrospective chart review.
METHODS: Forty-four eyes of 35 patients, > or =18 years of age, with open-angle glaucoma (primary open-angle, pseudoexfoliation, or pigmentary glaucoma), uncontrolled on maximum tolerable medical therapy, underwent an initial 360-degree SLT (SLT1), which was successful for > or =6 months, but eventually lost efficacy and was followed by a repeat 360-degree SLT (SLT2). Patients with prior argon laser trabeculoplasty or other glaucoma surgery, before or during the study period, were excluded. Intraocular pressure (IOP) measurements were recorded before each procedure and 1 to 4 weeks, 1 to 3 months, and 5 to 8 months posttreatment and 15 to 21 weeks after the initial SLT.
RESULTS: Reduction in IOP after SLT1 and SLT2 was significantly less with repeat treatment at 1 to 3 months, with average decreases of -5.0 and -2.9 mm Hg, respectively (P=0.01), but there were no statistically significant differences between treatments at the other equivalent time points. Using a definition of "success" as > or =20% peak IOP reduction, success rates for SLT1 and SLT2 were not significantly different. There was also no significant difference in eyes that received SLT2 6 to 12 months after SLT1 compared with those that received SLT2 12 months or more after SLT1.
CONCLUSIONS: Our findings suggest that repeat 360-degree SLT may be safe and effective after an initially successful 360-degree SLT has failed. These results may be achieved as early as 6 months after the first treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19295367      PMCID: PMC2714284          DOI: 10.1097/IJG.0b013e31817eee0b

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  9 in total

1.  Laser trabeculoplasty retreatment.

Authors:  P A Weber; G D Burton; A T Epitropoulos
Journal:  Ophthalmic Surg       Date:  1989-10

2.  Retreatment with argon laser trabeculoplasty.

Authors:  C U Richter; B J Shingleton; A R Bellows; B T Hutchinson; L P Jacobson
Journal:  Ophthalmology       Date:  1987-09       Impact factor: 12.079

3.  Therapeutic limitations of argon laser trabeculoplasty.

Authors:  A I Fink; A J Jordan; P N Lao; D A Fong
Journal:  Br J Ophthalmol       Date:  1988-04       Impact factor: 4.638

4.  The effect of repeat argon laser trabeculoplasty.

Authors:  P A Jorizzo; J R Samples; E M Van Buskirk
Journal:  Am J Ophthalmol       Date:  1988-12-15       Impact factor: 5.258

5.  Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions.

Authors:  M A Latina; C Park
Journal:  Exp Eye Res       Date:  1995-04       Impact factor: 3.467

6.  The effect of repeating full-circumference argon laser trabeculoplasty.

Authors:  R J Starita; R L Fellman; G L Spaeth; E Poryzees
Journal:  Ophthalmic Surg       Date:  1984-01

7.  Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes.

Authors:  T R Kramer; R J Noecker
Journal:  Ophthalmology       Date:  2001-04       Impact factor: 12.079

8.  Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective randomised clinical trial.

Authors:  K F Damji; K C Shah; W J Rock; H S Bains; W G Hodge
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

9.  Selective vs argon laser trabeculoplasty: hypotensive efficacy, anterior chamber inflammation, and postoperative pain.

Authors:  J M Martinez-de-la-Casa; J Garcia-Feijoo; A Castillo; M Matilla; J M Macias; J M Benitez-del-Castillo; J Garcia-Sanchez
Journal:  Eye (Lond)       Date:  2004-05       Impact factor: 3.775

  9 in total
  33 in total

1.  Repeatability of primary selective laser trabeculoplasty in patients with primary open-angle glaucoma.

Authors:  Neil Avery; Ghee Soon Ang; Simon Nicholas; Anthony Wells
Journal:  Int Ophthalmol       Date:  2013-01-31       Impact factor: 2.031

Review 2.  Selective laser trabeculoplasty: past, present, and future.

Authors:  A Garg; G Gazzard
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

3.  Selective laser trabeculoplasty.

Authors:  Jing-Ming Shi; Song-Bai Jia
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

4.  Clinical results of selective laser trabeculoplasty in silicone oil-induced secondary glaucoma.

Authors:  Miaomiao Zhang; Bin Li; Jianrong Wang; Wei Liu; Yan Sun; Xinyi Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-27       Impact factor: 3.117

5.  Intraocular pressure reduction after initial failure of selective laser trabeculoplasty (SLT).

Authors:  Marcelo Ayala
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-21       Impact factor: 3.117

6.  Update on laser trabeculoplasty.

Authors:  Fathi El Sayyad; Magdi Helal
Journal:  Middle East Afr J Ophthalmol       Date:  2009-07

7.  SELECTIVE LASER TRABECULOPLASTY--SHORT TERM EFFICACY AND SAFETY PROFILE IN OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION TREATMENT.

Authors:  Dorin Chiselita; Alina Cantemir; Anca Delia Pantalon
Journal:  Rom J Ophthalmol       Date:  2015 Jul-Sep

8.  West Indies Glaucoma Laser Study (WIGLS)-2: Predictors of Selective Laser Trabeculoplasty Efficacy in Afro-Caribbeans With Glaucoma.

Authors:  Tony Realini; Hazel Shillingford-Ricketts; Darra Burt; Goundappa K Balasubramani
Journal:  J Glaucoma       Date:  2018-10       Impact factor: 2.503

9.  Lasers in primary open angle glaucoma.

Authors:  Ramanjit Sihota
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

10.  Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial.

Authors:  Tony Realini; Gus Gazzard; Mark Latina; Michael Kass
Journal:  J Glaucoma       Date:  2021-07-01       Impact factor: 2.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.